---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022704"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-05-13T20:01:30+00:00"
generated_at: "2026-05-13T20:02:50.753578+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mira Pharmaceuticals announces positive Phase 1 results for Ketamir-2; plans Phase 2a in CIPN

## Summary
- Phase 1 trial in 57 healthy volunteers; all completed with no withdrawals or serious adverse events.
- Ketamir-2 half-life 2.5–7 hours; active metabolite nor-Ketamir-2 half-life 7–9 hours; supports once-daily dosing.
- DEA classified Ketamir-2 as not a controlled substance, eliminating scheduling barriers.
- Company preparing Phase 2a protocol for chemotherapy-induced peripheral neuropathy (CIPN) for FDA submission.
- Preclinical data showed Ketamir-2 superior efficacy vs. ketamine, pregabalin, and gabapentin in neuropathic pain models.

## SEC filing metadata
- accession: 0001493152-26-022704
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-05-13T20:01:30+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226022704/0001493152-26-022704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226022704/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022704
- JSON: https://secwatch.observer/filing/0001493152-26-022704.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.